Remote Ischemic Preconditioning for Aute Type A Aortic Dissection Surgery
ConditionAortic Dissection Type A
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorFujian Medical University
About this trial
The goal of this clinical trial is to learn if a technique called remote ischemic preconditioning (RIPC) helps protect organs during emergency surgery for acute type A aortic dissection (ATAAD). The main questions it aims to answer are:
Does RIPC reduce the risk of major complications after surgery, such as heart, brain, or kidney problems?
Is RIPC safe to use during emergency ATAAD surgery?
Researchers will compare the RIPC group to a control group (who will receive a placebo) to see if RIPC can reduce complications after surgery.
Participants will:
Receive either RIPC or a sham intervention during their surgery.
Be monitored for up to 30 days after surgery for complications.
Have follow-up visits at 3 months, 1 year, and then yearly for up to 5 years to track their recovery.
Eligibility criteria
Qualifiers
Age ≥18 years, with no restriction on sex;
Diagnosis of acute Type A aortic dissection requiring emergency surgery (symptom onset <14 days);
Ability to understand the study objectives, voluntary provision of written informed consent by the patient or a legally authorized representative, and willingness to comply with follow-up.
Disqualifiers
Traumatic or iatrogenic aortic dissection;
Previous open cardiac or thoracic aortic surgery;
Severe preoperative dysfunction of vital organs, such as persistent deep coma, abdominal compartment syndrome, or circulatory failure;
Severe comorbidities, including myocardial infarction within the past 7 days, stroke within the past 2 months; end-stage renal disease (eGFR <30 ml/min/1.73 m²); end-stage liver disease (total bilirubin >342 μmol/L or INR >2.0);
Trial design
Treatments tested in this trial
- Remote ischemic preconditioning (RIPC)
Treatment groups
1,296 Participants
are divided into 2 treatment groupsSponsors and collaborators
Fujian Medical University
Lead sponsor
The First Affiliated Hospital of Dalian Medical University
Collaborator
Xiamen Cardiovascular Hospital, Xiamen University
Collaborator
Source ClinicalTrials.gov